Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

Inclusion Criteria: * Subject who has received maintenance hemodialysis 3 times a week for at least 12 weeks (84 days) prior to the scheduled first day of the washout period. * Subject who can receive morning dialysis from the start of the washout period to the end of follow-up period. (Part 2) * Subject with pre-dialysis serum Pi level between ≥6.0 and \<10.0 mg/dL and be confirmed increase in serum Pi of ≥1.5 mg/dL after the maximum dialysis interval at the washout period week 1 or 2. (Part 2) * Subject who did not change the type or dose of any phosphate binder(s), any nutritional supplements or any other drugs with phosphorus reducing action for at least 4 weeks (28 days) prior to the scheduled first day of the washout period. * Subject who did not receive calcimimetics (e.g., cinacalcet HCl) for at least 12 weeks (84 days) prior to the scheduled first day of the washout period. * Subject taking native or active vitamin D (including vitamin D analogues), calcitonin agents or PTH agents must be on stable dose for at least 4 weeks (28 days) prior to the scheduled first day of the washout period. Exclusion Criteria: * Subject who has a history of severe gastrointestinal disorder, major gastrointestinal surgery, malabsorption considered influential on the absorption of the drug and nutrition in the gastrointestinal tract. * Subject who has a history of parathyroid intervention (e.g., parathyroidectomy \[PTx\], percutaneous ethanol injection therapy \[PEIT\]). * Subject whose dry weight loss \>5% within 12 weeks (84 days) prior to the scheduled start day of the washout period. * Confirmed serum intact PTH \>1000 pg/mL at the start of the washout period (only applicable for Part 2). * Subject whose last 3 measurement values at the separate day of pre-dialysis systolic/diastolic blood pressure before the scheduled start day of the washout period or during the washout period are all 180 mmHg or higher and 120 mmHg or higher. * Subject who has severe congestive heart failure (i.e., NYHA cardiac function classification Class III or severer). * Subject who experienced a myocardial infarction or major surgery excluding vascular access surgery within 12 weeks (84 days) prior to the informed consent signing. * Subject who has any of liver function tests (ALT, AST, T-Bil) out of range as indicated below at the screening (Part 1) or during the washout period, or patients with a complication of serious hepatic disease (e.g., acute and active chronic hepatitis, liver cirrhosis). AST: \>2×ULN, ALT: \>2×ULN, T-Bil: \>1.25×ULN * Subject with history or complication of malignant tumor (considered eligible if recurrence has not been observed for at least 5 years). * Subject with history of serious drug hypersensitivity, such as anaphylactic shock.